Research News

National brain tumour research funding needs to increase to £30-35 million a year

Filter

Clinical collaboration aimed at improving treatments for patients diagnosed with glioblastoma announced

Latest news categories

20 November 2019

Two pharmaceutical companies, KIYATEC, Inc. and CarThera, have announced today that they have entered into a clinical collaboration for the purpose of advancing innovation and improving treatments for patients diagnosed with glioblastoma.

The collaboration will focus on accelerating the development and validation of their emerging technologies to improve both the selection and effectiveness of drugs commonly recommended and used to treat the disease.

CarThera is currently conducting a multi-centre clinical study of its novel ultrasound technology, SonoCloud-9, designed to increase the permeability of the blood brain barrier to improve the delivery of chemotherapeutic agents to the brains of patients with recurrent glioblastoma.

KIYATEC is conducting a multi-centre clinical study of its ex vivo 3D cell culture technology to accurately predict pre-treatment, patient-specific response to recommended standard of care cancer drugs for newly diagnosed and recurrent glioblastoma.

Both are committed to ensuring brain cancer patients receive most appropriate drug therapy at the right time and efficacy is maximised to the fullest therapeutic potential.

The two companies were brought together by one of the world’s leading neuro-oncology and glioblastoma experts, John de Groot, M.D., professor and chairman ad interim of The University of Texas MD Anderson Cancer Centre, who recognized the synergistic nature of their respective clinical initiatives.

“As someone who cares for patients with glioblastoma, I applaud the efforts of CarThera and KIYATEC to bring evidence-based advances to the clinic for the purpose of improving outcomes for patients with glioblastoma,” said Dr. de Groot. “I envision these two technologies as being complementary with the potential to transform the way in which neuro-oncologists manage glioblastoma patients.”